Prasugrel + Placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Anemia
Conditions
Sickle Cell Anemia
Trial Timeline
Jul 1, 2010 → Jun 1, 2011
NCT ID
NCT01167023About Prasugrel + Placebo
Prasugrel + Placebo is a phase 2 stage product being developed by Daiichi Sankyo for Sickle Cell Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01167023. Target conditions include Sickle Cell Anemia.
What happened to similar drugs?
4 of 20 similar drugs in Sickle Cell Anemia were approved
Approved (4) Terminated (9) Active (8)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01794000 | Phase 3 | Terminated |
| NCT01167023 | Phase 2 | Completed |
Competing Products
20 competing products in Sickle Cell Anemia